Our vision is to democratize cell-based therapies for all patients.
Cell BioEngines, Inc., founded in Dec 2022, is a clinical-stage biotech company focused on developing allogeneic 'off-the-shelf' stem cell and its derived therapies as ‘drugs’ for human disease treatment.
Human body is made of ~37.2 trillion of functional cells and many incurable health problems occur due to irreversible damage to these cells. Our mission is to achieve a universal stem cell foundation platform where we can precisely generate any desired human cell state on demand and at scale, to repair or replace damaged tissue.
The company utilizes a ‘plug-and-play’ epigenetic regulatory platform to convert ‘non-gene-modified’ donor blood stem cells into rare, potent clinical-grade cells for therapeutics, primarily oncology and regenerative medicine applications. Our strategy focuses on overcoming donor source availability, potency and scalability challenges to expand access to HLA-compatible cell therapies.
OUR UNIQUE STRATEGY
We Develop Cell-based Products Both Within Our Company and Through Our Partner Company
Our Business Model is Focused on Expanding Our Portfolio of Product Opportunities
Allows Diversified Development of Multiple Programs Spanning Several Large Therapeutic Markets
OUR APPROACH
Cell Technology
Stem Cells Expansion, Differentiation and De-differentiation to Manufacture Rare, Potent Cells for Clinical Use
Product Pipeline
Cell-based Therapeutic Product Candidates to Transform Medicine and Healthcare
Time and space are not conditions of existence, time and space is a model for thinking
Albert Einstein
Our Goals
More than 1 disease at a time
More than 1 disease at a time
More than 1 disease at a time
We are therapeutic area agnostic which allows us maximum flexibility to focus on advancing cutting-edge stem cell-derived therapeutics approaches in oncology and regenerative medicine.
Decrease time to development
More than 1 disease at a time
More than 1 disease at a time
Allows us to pursue a broad range of products and product candidates with high clinical and commercial potential. This broad and deep diversification lowers the time to development and overall risk profile of the company.
Lower translational costs
More than 1 disease at a time
Lower translational costs
Low cost manufacturing enables us to act quickly to seize time-sensitive opportunities and provides us with a wider range of options from which to select the most ideal financial structure for each product.